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1. Introduction  
Looking at the prognosis of Cystic Fibrosis (CF) from the clinician's point of view is very 
relevant. Median predicted survival age of CF increased from 6 months when the disease 
was first described (1938) to 12 years in 1970 and over 35 years in 2010 in the United States 
of America (Davis, 2006). Three types of factors weigh on this prognosis, which is 
conditioned by lung disease: factors linked to the quality of care management, to genetics 
and to the environment. It has been estimated from studies in twins and siblings that the 
relative influence of the latter two is roughly equivalent. Though pollution may have 
increased in certain areas, and lighter forms of CF are now being detected by neonatal 
screening and in clinics where nasal potential measurements are widely available, their 
impact is limited and can not account for the spectacular changes in life expectancy. Thus, 
this improvement is due essentially to a better care management. Quality of care is the main 
determinant of CF prognosis.  
The question of prognosis is almost invariably the very first that parents of a newly 
diagnosed CF infant will ask their physician, whose task to answer in a sensitive and 
sensible fashion is by no means easy. This question is also at the heart of daily concerns of 
the clinician, who has to take its determinants into consideration not so much in view of 
their fascinating underlying mechanisms (e.g. modifier genes) but rather to the extent they 
can give grip to improved care. 
2. How to express CF prognosis? Median predicted survival:  
Facts, limitations and hopes  
CF is a serious disease, which reduces life expectancy. Parents have often already found on 
the internet the associated 'Median predicted survival', which is the estimated duration of 
time until 50% of a given population dies. This given number of years has the effect of a 
guillotine and haunts their thoughts. For CF patients in 2008, it was 37.4 years in the US 
(CFF Registry, 2008), 38.8 years in the UK (UK CF Registry, 2008) and 46.6 in Canada (44.8 
years after excluding adult diagnoses) (Canadian CFF, 2008). However, for a number of 
methodological issues, it is difficult to compare results of national registries. Evaluating 
cohorts on the basis of the presence or absence of pancreatic insufficiency was recently 
suggested as a way to help to overcome some of the current limitations (Buzzetti et al., 2009). 
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Limiting the analysis to patients homozygous for the F508del mutation could be even 
'cleaner' (Zelin et al., 2010; Lebecque et al., 2010). It is important to note that over the past 60 
years, median predicted survival has actually increased in a continuous fashion by almost 6 
years every decade (Davis, 2006). Part of this improvement is probably linked to the 
increased detection of milder forms of the disease. As proposed for the comparison of 
registries, it would be interesting to study the data of only those patients homozygous for 
the F508del mutation. For four reasons developed below, this brutal landmark has limited 
value in an individual patient. 
2.1 Cohort effects 
Cohort survival curves consistently show that survival continues to improve with each 
successive birth cohort over the decades. However, this effect is not taken into account by 
current survival curves. As a result, advice based on the latter could be unduly pessimistic. 
This has led authors to model the trend observed in cohort survival curves and to 
extrapolate a median survival for recent cohorts. Accordingly, a median life expectancy of 
the order of 40 years was predicted for newborns in 1990 in the UK (Elborn et al., 1991). This 
proved to be realistic and updated extrapolation for the birth cohort of the year 2000 
predicts a median survival of 50 years (Dodge et al., 2007). Recent work has further 
validated this approach (Jackson et al., 2011).  
2.2 Wide heterogeneity of the disease 
Median predicted survival does not take into account the vast heterogeneity of CF. Yet the 
latter has long been recognized, even amongst patients homozygous for the F508del 
mutation (Kerem et al., 1990; Johanssen et al., 1991). When diagnosing a new patient carrying 
2 CF-causing mutations, this variability renders precise individual prognosis almost always 
impossible.  
2.3 Quality of life 
The raw median predicted survival rate says nothing about quality of life. In CF, pulmonary 
function is often used as a surrogate for survival, with FEV1 remaining the single most 
useful parameter (Kerem et al., 1992). Though insensitive to early stages of the disease, 
spirometry is widely available, inexpensive, non-invasive and very reproducible. It can 
usually be performed from the age of 5 and upwards. FEV1 has the advantage of reflecting 
pulmonary involvement, thereby conditioning prognosis, throughout the whole course of 
the disease. The rate of FEV1 decline might be an even stronger surrogate for survival (Liou 
et al., 2001; Schluchter et al., 2002; Rosenbluth et al., 2004). 
Quality of life is at least as important as its length. For every human being, it is largely 
conditioned by how an individual handles the careful balance of renunciations, and accepts 
these. Its precise and fine perception inevitably escapes all questionnaires. Specific tools 
developed over the past 20 years cannot presume to its assessment but can help discern the 
impact of new treatment modalities and are increasingly being used in this context (Abbott 
et al., 2011). This also implies that, given the choice between equally efficient treatments, the 
least invasive treatment and follow-up modalities are to be favoured (Wainwright et al., 
2011). Under close supervision and for adequately selected patients, home intravenous 
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antibiotic treatment is a less disruptive alternative to hospital admissions. Though fatigue 
can be worse for home participants, home treatment has been associated to improvement in 
quality of life (Balaquer et al., 2008). At all stages of this complex long-term disease, a holistic 
approach of the care management of both the patient and his family is essential (Bush et al., 
2006; Cohen-Cymberknoh et al., 2011). 
2.4 Hope for a curative treatment 
Predicting survival of a disease based on the past and present data bypasses the possibility 
of discovering a cure. Despite all prognostic improvements linked to progress in follow-up 
and symptomatic treatment of CF, it remains imperative to discover a cure for respiratory 
disease of CF, for at least 3 reasons: i) current treatment is increasingly cumbersome, 
'devouring' about 2 hours every day on average; ii) the cost of CF treatment is constantly 
rising, leading to fears that there may be increasing limitations as to its availability, even in 
richer countries; iii) some patients still experience a much more rapid FEV1 decline. The 
approach favoured today is that of the search for pharmacological agents capable of 
circumventing the consequences of genetic anomalies as determined by CFTR gene class 
mutations (Amaral, 2011; Rogan et al., 2011). The principle is to interrupt 'the source' of the 
cascade of events that leads from an ionic transport anomaly in the respiratory epithelium to 
lung destruction. Treatment tailored to the type of mutation appears today reasonably 
within reach (Accurso et al., 2010). Should this eventuality become a reality, the prognosis of 
patients still free of significant pulmonary lesions would be radically transformed. 
3. Causes of death in CF  
Over 95% of known causes of death in CF (including data following lung transplantations of 
CF patients) are linked to involvement of the respiratory system (CFF Registry, 2000). 
Amongst the specific and much rarer causes of death, feature complications of liver disease, 
dehydration and intestinal obstruction in countries where physicians have little knowledge 
of CF (Verma et al., 2000). 
4. Prognostic factors  
A pragmatic way of looking at prognostic factors of CF is to distinguish those that are linked 
to the quality of care management and those on which care management has little (e.g. 
environmental factors) or no grip (genetic factors) (Wolfenden et al., 2009). Figure 1 gives an 
overview of prognostic factors in CF. 
Three aspects of the discussion are worth mentioning i) interactions between factors are 
numerous and their complex statistical evaluation study has probably been too shallow in 
many publications; ii) the evaluation of the role of certain less easily quantifiable factors, 
such as treatment adherence, escapes usual means of analysis; iii) our choice is to focus on 
factors that appear essential to a clinician. The complexity of interactions between the 
different factors is clearly illustrated by the example of the impact of passive smoking on 
respiratory function. Although the deleterious effects of passive smoking are well 
established, they vary according to CFTR genotype and certain alleles of modifying genes 
(Collaco et al., 2008). Moreover, several studies demonstrated a link between passive 
smoking and socio-economic status (Smyth et al., 1994). 
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One example of 'the clinician's choice' in the discussion is not to dwell on the often reported 
issue of a 'female disadvantage' (Rosenfeld et al., 1997; Mehta et al., 2010; Olesen et al., 2010), 
which may not concern adult diagnosed CF patients (Nick et al., 2010). Numerous 
hypotheses have been brought forward to account for it, without any practical impact to 
date. Furthermore, though this might have been achieved at the price of a higher burden of 
treatment in females (Olesen et al., 2010), there is evidence that modern intensive treatment 
may result in similar key clinical parameters for the two genders (Verma et al., 2008; Olesen 
et al., 2010). 
 
Fig. 1. Prognostic factors in CF  
5. Good care management of CF  
Early and mostly optimal management of CF is thus the principal reason for the improved 
prognosis observed over the past decades. Comprehensive follow-up and progress in 
symptomatic treatment proved essential. Antibiotics are the mainstay of CF therapy. In view 
of the complexity of this multisystemic and in many ways unique pathology, optimal 
management is only possible in truly specialized structures. Limiting the impact of 
economic status on treatment is an important issue. Most impressively, a pioneer clinician 
had already specifically stressed the importance of every single one of the above-named 
factors as early as 1974 (Crozier, 1974).  
Taken in isolation and often combined to other factors (see discussion below), several 
complications can be linked to an accelerated rate of FEV1 decline. Their awareness, 
prevention or early detection followed by optimal management carries the potential to 
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reduce the rate of FEV1 decline. This is well illustrated by the case for CF-related diabetes 
(CFRD) over the past 20 years. At one large CF centre, early detection and optimal 
management of CFRD resulted in a decrease on its impact on mortality and the 
disappearance of a sex difference in mortality (Moran et al., 2009). 
Two factors in particular, chronic airway colonisation by Pseudomonas aeruginosa (PA) and 
malnutrition, have such spontaneous prevalence and such prognostic impact, that their 
prevention constitutes one of the major objectives of CF care management.  
Several medications have been associated to slowing down the rate of FEV1 decline: dornase 
alpha (Konstan et al., 2011), ibuprofen (Konstan et al., 1995; Konstan et al., 2007), 
azithromycin (Hansen et al., 2005) and inhaled corticosteroids (De Boeck et al., 2011). This 
does not mean that all patients will benefit from them. In addition, possible side-effects in 
the long-term have to be kept in mind (cf. e.g. ibuprofen). Also, it cannot be inferred that 
other drugs are necessarily ineffective: they may simply not have been subjected to 
appropriate studies, which occasionally may be due to commercial reasons or ethical 
concerns (e.g. physiotherapy).  
5.1 Early diagnosis: CF newborn screening (NBS) 
A number of studies using bronchoalveolar lavage (BAL) markers of infection and 
inflammation, lung function tests or computed tomography of the chest have documented 
that significant lung damage occurs very early in many, even asymptomatic, infants (Khan 
et al., 1995; Ranganathan et al., 2001; Davis et al., 2007; Mott et al., 2009). The results of two 
recent studies concerning very young infants who were investigated routinely after CF 
diagnosis by NBS are particularly striking (Sly et al., 2009; Stafler et al., 2011). Unsuspected 
positive cultures were found in 21-27% of them, there was evidence of airways 
inflammation with BAL neutrophilia in most patients and CT evidence of bronchial 
dilatation in 18.6%. 
CF is a progressive disease for which symptomatic treatment has proven to have a real impact 
albeit of partial efficiency. So, starting treatment as early as possible is meaningful. CF NBS is 
now available throughout the USA and in many European countries. For those newborns 
carrying a genotype clearly associated with the disease, benefits of neonatal screening has long 
been proven in nutritional terms. Respiratory benefits have only recently been acknowledged 
(Accurso et al., 2005; Rosenfeld et al., 2010), as these were temporarily obscured by a 
publication indicating an increased risk of early chronic colonisation by PA in screened 
newborns (Farrell et al., 2003). This increased risk was eventually linked to the lack of 
measures aiming to limit cross infections in that particular centre and subsequent studies 
failed to confirm it (Siret et al., 2003; Sims et al., 2005; Baussano et al., 2006; Collins et al., 2008). 
In countries with a high level of medical care, neonatal screening enables clinicians to diagnose 
CF in infants before the age of 2 months, with demonstrable benefits (Sims et al., 2007). 
5.2 The case for CF care centres 
5.2.1 CF centres are necessary 
CF NBS is universally coupled with immediate referral to a specialist centre. Guidelines and 
international consensus all emphasize this to be the key to efficiency for all CF programs 
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(Castellani et al., 2009; Comeau et al., 2007). Even outside the context of CF NBS, early 
referral to a specialist healthcare centre is considered as a major prognostic factor as 
highlighted in consensus reports on optimal management of CF (Littlewood, 2000; Kerem et 
al., 2005; Colombo et al., 2011). Though this has long been supported by a number of 
common sense reasons and has been mentioned as a model for the management of complex 
diseases (Schechter et al., 2005), most published studies concerning the impact of this 
centralization on lung disease are either biased due to comparison with historical controls, 
and/or probably underpowered (Hill et al., 1985; Nielsen et al., 1988; Walters et al., 1994; 
Collins et al., 1999; Merelle et al., 2001; Van Koolwijk et al., 2002).  
Two studies avoid these pitfalls. Mahadeva et al. compared two groups of adults who had 
either received continuous care from paediatric and adult CF centres (n=50) or had received 
neither paediatric nor adult centre care for their CF (n=36). Excluding body mass index as a 
covariate, FEV1 was significantly better in the first group (Mahadeva et al., 2000). More 
recently, a Belgian retrospective multicentre study clearly showed that earlier referral of 
children suffering from CF to specialist care was associated with significant pulmonary 
benefits (Lebecque et al. , 2009). Children referred 'early' (less than 2 years after diagnosis) 
had a better FEV1 (86.7% pred. ± 19.4 vs. 77.2% ± 22.4, p=0.01) and a lower prevalence of PA 
(17.5% vs. 38.6 %, p<0.05) than carefully matched patients referred later.  
5.2.2 CF centres might not be sufficient 
Large differences between outcome variables obtained from the different centres have been 
recognized for a long time (Bauernfeind et al., 1996) and are now drawing considerable 
attention as they may provide an opportunity to develop quality improvement initiatives. 
Striking illustrations of this outcome heterogeneity are provided by recent data from the 2007 
US Registry (CFF Registry, 2007 – public data), allowing for comparisons between centres: i) 
mean FEV1 (% predicted) for CF children aged 6-17 years ranged from 75 to 103% (national 
average: 92.6%, reference values: Wang & Hankinson) ii) the percentage of patients under 20 
years of age with a BMI < 5th percentile ranged from 32 to 83% (national average: 52.7%) iii) 
MRSA infection rate ranged from 6 to 42% (national average: 21.2%). These differences 
persisted after taking into account socio-economic factors. Similar features can be derived from 
the CF German Registry where a quality management program with an overall coverage of 
82% for the year of 2005 confirmed considerable differences between centres in terms of key 
parameters (Stern et al., 2008). For instance, the percentage of children (6-18 years) with an 
FEV1 above 80% of the predicted value ranged from 20 to 100% in centres treating less than 50 
patients and from 35% to 100% in larger centres. Globally, the mean FEV1 in this age group 
was 88% of the predicted value. A recent Belgian multicentre study confirmed the broad 
outcome differences between reference centres within this small country, where corresponding 
values for FEV1 in children reportedly ranged from 74% to 95% predicted (Lebecque et al., 
2009) while the prevalence of PA (last visit of the year) ranged from 5 to 46% and the mean 
weight expressed as percentage of ideal body weight ranged from 88% to 100%.  
5.2.3 Marked differences in clinical results between CF centres: Why? 
One report of 18,411 patients followed in 194 North American centres in 1995 showed that 
close monitoring and heavier treatment (more frequent antibiotics in particular) clearly 
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characterized those north-American centres with better clinical results (Johnson et al., 
2003). It is interesting to note that this more intensive management included two 
modalities which do not correspond to standard management: frequent prescription of 
nedocromil and more common prophylactic prescription of inhaled antibiotics, 
particularly in patients with still little pulmonary involvement. The use of nedocromil in 
CF is not well documented in the literature, neither is the potential of giving prophylactic 
inhaled antibiotics, which is discussed a little further in this chapter. Another North 
American study concerned 837 children aged 6 to 12 years (Padman et al., 2007), whose CF 
centres were classified according to the children's FEV1 values in 2003. The analysis also 
suggested that closer follow-up starting before the age of 3 years was characteristic of 
those centres with the best functional results. This 'more attentive and more active 
'attitude' is in line with current standards of care, which are derived as much as possible 
from evidence-based medicine (Littlewood, 2000; Kerem et al., 2005; Littlewood, 2005; 
Tiddens, 2009). 
In 2002, the CFF launched an innovative Quality Improvement (QI) initiative, which 
included the vision statement that within 5 years, life expectancy of CF patients could be 
extended by 5-10 years through the consistent implementation of existing evidence-based 
clinical care (Quinton, 2007). However, evidence-based medicine has its limitations and 
possible stumbling blocks (Driever, 2002; Saarni et al., 2004; Miles et al., 2008; Shahar, 2008; 
Miles et al., 2011), in particular when it concerns diseases as complex as CF for which 
numerous therapeutic modalities have simply not yet been adequately studied (Cheng et al., 
2000; David, 2001; Briggs et al., 2006; Kraynack et al., 2009). Best practice remains 
individualized in part, although a coherent foundation of evidence-based medicine is 
absolutely necessary.  
One comparative study of 3 CF centres illustrates how even beside care standards, clinician 
intuition can lead to potentially judicious choices that deserve prospective studies. A better 
nutritional status was indeed linked to the prescription of dornase alpha (Pulmozyme ®) 
under the age of 2 years (Padman et al., 2008), whereas the effects of Pulmozyme in this age 
group have only been reported in one limited study (Berge et al., 2003) where 9 infants were 
given the drug for 2 weeks. The necessity to conceive and study new strategies stems from 
the fact that current ones are relatively powerless in preventing pulmonary lesions in early 
diagnosed infants (Stick et al., 2009). 
Information concerning the standards of CF care is widely available as are new drugs in rich 
countries. Differences in clinical results between various CF centres must therefore have a 
different origin. One can suspect subtle combinations of several factors resulting in small 
differences in interventionist attitudes. Beside adequate means i.e. infrastructures and 
human resources, optimal care requires a careful organisation (structure of the centre, 
coherence of attitudes, multiple fail safe systems etc.) necessitating considerable long-term 
thoughtful investment of all those involved. 
5.2.4 Variability of outcomes in CF centres: Benchmarking as a right to patients  
It is not possible for a CF clinic to function without landmarks. Specific databases prove to 
be very precious by giving immediate access to progress over time and by age group of 
essential parameters, thereby constituting a sort of 'compass' for measures that could be 
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taken to improve care management. Although limiting the objective to FEV1 improvement 
would be reductive, it clearly remains an essential parameter. The FEV1 of patients aged 6-
18 years old (Figure 2) is a particularly relevant landmark for the 3 following reasons: i) very 
few patients die or require transplantation prior to that age ii) a significant proportion of 
adults has not benefited from immediate specialized care iii) adolescence is a particularly 
high risk time period with regard to deterioration of respiratory function. Appropriate 
indicators to define nutritional outcomes are also necessary (Lai et al., 2008). If they are to be 
used to compare CF centres, these indicators have to be adjusted for risk factors - which 
does not change the overall outcome variability of CF centres (Schechter et al., 2002) - and 
several years should be taken into consideration, in order to appreciate their coherence and 
tendencies.  
 
Fig. 2. Lung function in children followed-up at St Luc  (last visit of the year, reference 
equations from Wang et al. for females through age 15 and males through age 17, and 
Hankinson et al. at older ages)  (Wang et al., 1993; Hankinson et al., 1999).  
The differences in mean FEV1 observed in children from various CF centres can exceed 
20% of predicted values. Recent data can help to perceive the implications of such 
differences: i) some centres now report a mean annual FEV1 decline around 1% (Que, 
2006) ii) in terms of FEV1 (expressed in % pred.), improvements from baseline observed 
in two major randomized controlled trials of inhaled dornase alfa and tobramycin were 
less than 4% and 5% respectively (Fuchs et al., 1994; Ramsey et al., 1999) iii) in the USA, 
from 1990 to 2008, median FEV1 at 12 years of age increased by 14 % predicted. Thus the 
prognostic significance of the differences between centres is major, also in terms of life 
expectancy. For this reason, public access to these data can be considered as a right to the 
patient and/or parents. In 2006, the outcomes data from the CF Foundation registry 
became public on the foundation’s website, with an accompanying warning against 
simplistic interpretations. This choice bore witness to the priority given to the patients. 
Their health is at stake, and keeping them informed has to take precedence over the risk 
of embarrassing some physicians. In the USA, the fear that some patients may leave CF 
centres with average performance has not materialised: patients and their family 
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5.2.5 'Good enough' care for CF does not exist: Towards a culture of improvement 
Benchmarking, which is the process of identifying practices associated with the best results, 
may help to understand why certain centres obtain better clinical results. Not only can it be 
considered a right to the patients, it can also serve as an incentive to CF centres to increase their 
efforts to improve quality of care delivery. In the USA, most CF healthcare providers actually 
accepted it as a call to action (Schechter et al., 2005). Public release of meaningful adjusted 
clinical outcomes data has been used in other fields of medicine, such as cardiac surgery, as a 
means to stimulate improvement efforts within the medical profession (Ferris et al., 2010). 
Others have advocated 'softer' uses of benchmarking which do not require to be channelled via 
public data (Stern et al., 2011). In the field of CF, benchmarking is not an easy task. It is possible 
when based on well-established CF registries but issues related to quality control and missing 
data obviously remain crucial (van der Ent, 2008). A number of methodological issues make it 
even harder to compare data from different countries. These include (but are not limited to) the 
population coverage level, the choice of reference equations, the type of subjects included in the 
registry (an increasing number of patients with milder forms of the disease are now being 
identified in some countries through wide access to CFTR gene sequencing and nasal potential 
difference measurements, or via CF NBS), a lack of uniform definitions of specific items (FEV1 
has been recorded as the last, the best, the mean or the average of the best value for each quarter 
of the year; normal FEV1 has been defined as  80% or  90% of the predicted value in different 
registries) or of clinical conditions (hepatopathy, CF-related diabetes, pulmonary exacerbation), 
differences in age stratification (in the UK, adults are defined as patients  16 years old), 
inclusion or exclusion of lung transplanted patients ('another disease'), wide heterogeneity of 
CFTR mutations throughout the world, etc. There is indeed an obvious need for standardization 
in data collection if we are to compare different registries meaningfully. The ever present need 
to 'always try to do better' that animates so many clinicians and paramedics involved in caring 
for CF patients has led to the development of several QI initiatives. The latter have tended to 
improve key indices concerning either nutrition or respiratory function, but can also have other 
objectives such as a greater involvement of patients as partners in care, by sending them for 
example a copy of their own medical records (Treacy et al., 2008). Guidelines and evidence-
based medicine provide the directions in which changes for QI should be made. Various 
strategies can be put into place as part of these QI initiatives (Quinton, 2004; VandenBranden, 
2004; Schechter, 2004; Quinton et al., 2007; Britton et al., 2008; Schechter et al., 2010; Kraynack et 
al., 2009; Quon et al., 2011). They all rely on adequate infrastructures, the acknowledgement that 
changes are needed, relevant and quantifiable objectives identified on the basis of the centre's 
known clinical outcomes, the deployment of the necessary means and an objective evaluation of 
the various steps undertaken. Taking into consideration identified obstacles to optimal 
treatment (Zemanick et al., 2010), trends of medication use over time (Konstan et al., 2010), and 
the considerable differences in treatment practices (Borsje et al., 2000) or in clinical approach 
between specialized CF centres (Kraynack et al., 2011) could nurture reflection and help to 
identify and better discern the objectives and means to be put into place. 
5.3 Tools and challenges 
The range of responsibilities of a team dedicated to CF patients is vast, in keeping with the 
complexity of this chronic disease. Close and comprehensive follow-up enables an early 
start of an efficient symptomatic treatment. Guidelines and specific databases belong to 
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those tools that are essential to the clinicians. The importance of the latter can not be 
overemphasized (Kerem et al., 2005; Quinton et al., 2007; Leal et al., 2007; Tiddens, 2009).  




Fig. 3. Specific database provide instant access to critical information at the individual level 
and at the level of the clinic as a whole. a. Current treatment modalities occasionally lead to 
sustained very long-term improvement of both FEV1 and BMI. b. They can also allow 
prolonged survival in stable conditions despite severe pulmonary lesions (this patient 
eventually benefited from a lung transplant following recurrent life-threatening 
haemoptysis). c: This screen summarize bacteriological findings of a given patient over 5 
years, also allowing to determine at a glance the state of Pseudomonas aeruginosa infection 
according to a meaningful classification (Lee et al., 2003). d: Instant access to key parameters 
at the scale of the whole clinic. 
In the setting of the clinic, visualizing with a simple click trends of essential parameters such 
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Regularly updated guidelines and in-depth reviews are essential resources. They cover most 
areas including standards of care (Kerem et al., 2005), diagnosis (Farrell et al., 2008), adult 
management (Yankaskas et al., 2004), care of infants diagnosed by CF NBS (Accurso et al., 
2009; Sermet-Gaudelus et al., 2010), nutrition (Sinaasappel et al., 2002; CF Trust, 2002; 
Stallings et al., 2008), antibiotic therapy (CF Trust, 2009), respiratory infections (Ramsey et al., 
2003), by Pseudomonas aeruginosa in particular (Döring et al., 2000; Saiman et al., 2003; Döring 
et al., 2004; CF Trust , 2004; Hoiby et al., 2005), microbiology laboratory standards (CF Trust 
2010), pregnancy management (Edenborough et al., 2008; Lau et al., 2010) or complications 
such as Allergic BronchoPulmonary Aspergillosis (ABPA) (Stevens et al., 2003), diabetes 
(Moran et al., 2010), pneumothorax or haemoptysis (Flume et al., 2010). 
5.3.1 Challenge 1: Postpone chronic colonisation by Pseudomonas aeruginosa 
The reasons for which PA has a predilection for the lungs of CF patients are still unclear 
(Gibson et al., 2003). Its presence can often be detected early, at times within the first few 
months of life, even in the absence of any symptom. It will usually be isolated within the 
first 3 years (Burns et al., 2001; Dakin et al., 2002; West et al., 2002; Hilliard et al., 2007; Sly 
et al., 2009; Stafler et al., 2011). A prospective study has indicated that 90% of CF children 
aged 4 years and above presented at least 1 positive culture for PA (Li et al., 2005). The 
early isolates of PA are generally non-mucoid and antibiotic susceptible. However, PA 
tends to colonise the airways of CF patients in a chronic, irreversible, fashion often 
associated to a change to a mucoid phenotype. At this stage, pulmonary function usually 
worsens and clinical symptoms become evident. Early detection of PA is crucial as there 
is a window of opportunity for effective eradication at this stage (Koch, 2002; Li et al., 
2005). 
Chronic PA colonisation is associated with a lower FEV1 in childhood (Kerem et al., 1990), 
an accelerated rate of FEV1 decline (Pamukcu et al., 1995; Kosorok et al., 2001; Emerson et 
al., 2002), a shorter median life expectancy (CFF Registry, 1996; Emerson et al., 2002) and 
much higher treatment costs (Baumann et al., 2003). Preventing this colonisation is 
considered the most important challenge for the CF clinician, as it frequently determines 
the patient’s future quality of life and long-term survival (CF Trust 2002; Koch, 2002). The 
current approach relies on two strategies (Frederiksen et al., 1999): i) paying attention to 
segregate patients on bacteriological grounds in order to limit the risk of cross-infections 
(West et al., 2002; Conway et al., 2008), ii) early antibiotic treatment at the time of the first 
PA colonisation (Littlewood et al., 1985; Valerius et al., 1991; Frederiksen et al., 1997; Lee et 
al., 2004). A number of regimens have been evaluated (Stuart et al., 2010) but there is no 
consensus about the best combination, dosage, or length of treatment course. An initial 
treatment protocol combining nebulised colistin with oral ciprofloxacin for 3 months is 
widely used. Combining this approach with intravenous antibiotics has also been 
reported, with a 5-year failure rate of only 12% (Douglas et al., 2009). A prerequisite for 
this approach is a close bacteriological follow-up, with a time lapse between visits that 
cannot exceed 3 months. This interval is shorter (up to monthly) in many centres. An 
aggressive approach based on repeated BAL has not proven useful (Wainwright et al., 
2011). The 20% failure rate of the more commonly used approach (Frederiksen et al., 
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It is paradoxical that prophylactic antibiotic therapy directed against PA has only been the 
subject of 1 retrospective study (Heinzl et al., 2002) while prophylaxis against Staphylococcus 
aureus, whose threat is yet much easier to manage, has been investigated and hotly debated. 
The Austrian study was in fact very encouraging but the same group reported that long-
term gentamicin inhalation in CF children was associated with reversible raised urinary N-
acetyl-beta-D-glucosaminidase (NAG) activity, consistent with subtle subclinical renal 
tubular damage (Ring et al., 1998). Tobramycin and amikacin however have lower renal 
toxicity than gentamicin and long-term use of high doses of inhaled tobramycin (TOBI) are 
now considered safe (Prober et al., 2000). There are several theoretical arguments that make 
long-term inhaled prophylactic antibiotic therapy attractive (Lebecque et al., 2008). Based on 
the use of low doses of Tobramycin or Amikacin, this approach has progressively been put 
into place at our centre over the past 20 years, and has probably contributed, along with 
other factors, to a distinctly low rate of chronic colonisation rate by PA in patients under 18 
years of age (<5% for more than 10 years, according to Lee's definition) (Lee et al., 2003).  
5.3.2 Challenge 2: Maintain adequate nutrition 
The poorer prognosis associated with being relatively underweight has long been 
recognized in CF children (Kraemer et al., 1978). An overall parallelism exists between 
respiratory function and nutritional status progress over time (Zemel et al., 2000; Steinkamp 
et al., 2002; Konstan et al., 2003; Milla, 2004; Pedreira et al., 2005). While severe pulmonary 
disease seriously compromises the maintenance of a satisfactory nutritional status, proof of 
the opposite has also been demonstrated: maintaining a good nutritional status promotes 
respiratory function preservation. Evidence of the possible influence of maintaining a good 
nutritional status was first suggested by a comparison of the CF centres of Boston and 
Toronto (Corey et al., 1988). In Toronto, CF patients had better respiratory function and were 
better fed, and the main difference in management appeared to be the lack of fat restriction 
in the Canadian hospital. Maintaining an adequate nutritional status has become a priority 
of CF care. 
5.3.3 Many other challenges… 
Early detection and adequate management of poor clinical course find their place here, 
along with appropriate management of complications, particularly those linked to an 
accelerated rate of FEV1 decline as in ABPA (Kraemer et al., 2006), diabetes (Milla et al., 
2000), gastro-esophageal reflux (Levy et al., 1986), colonisation by Burkolderia cenocepacia 
(Ledson et al., 2002; Courtney et al., 2004) non-mucoid strains in particular (Zlosnik et al., 
2011), or by MRSA (Dasenbrook et al., 2008). In the same vein it is worth insisting on the 
vulnerable period spanning from pre-adolescence to adolescence (Konstan et al., 2007). The 
rate of FEV1 decline is faster at that time, and the various reasons for which this is 
considered a risk period should especially mobilise the attention and energy of the care 
management teams (Segal, 2008). In the context of CF, ABPA diagnosis is often delicate, (de 
Almeida et al., 2006; Thia et al., 2009) as many features overlap with those of infective 
exacerbations in CF, but it is important: failing to recognize ABPA can lead to irreversible 
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The prevention of cross-infections is a daily preoccupation that predetermines the detailed 
organisation of the CF centres. One of the major challenges is to limit Burkholderia cepacia 
complex (BCC) infections. The prognostic significance of colonisation by B. cenocepacia is 
particularly dreaded, as its presence is associated to an accelerated rate of FEV1 decline and 
a clinical picture that is often fatal (cepacia syndrome) (Isles et al., 1984) and can affect 
patients up to then in very good health. In addition, B. cenocepacia is a cause for increased 
mortality following lung transplantation (Aris et al., 2001; Boussaud et al., 2008). Other 
germs of the BCC group such as B. multivorans or B. dolosa have a less gloomy effect on 
prognosis but have exceptionally also been associated to the occurrence of a cepacia 
syndrome (Zahariadis et al., 2003; Blackburn et al., 2004; Kalish et al., 2006). 
Several other essential factors are involved in global care management. There is no 
equivalent long-term illness   to CF today in terms of the heavy burden of its symptomatic 
treatment. In a recent US study, adult patients - of whom only half had performed airway 
clearance - reported a mean time spent on treatment activities of 108 minutes per day 
(Sawicki et al., 2009). Though very difficult to assess (Modi et al., 2006), treatment adherence 
is undoubtedly a key issue in CF (Eakin et al, 2011) and requires permanent assessment and 
support (Pendleton, 2000). There is no magic recipe, but this subject has to be bridged at 
every consultation, in an open manner, with empathy and as part of a 'therapeutic alliance' 
(Lask, 1994; Cohen-Cymberknoh et al., 2011). Another objective is to be able to propose 
psychological and/or social support in response to specific situations, either linked to the 
disease or impacting on treatment in real life.  
5.3.4 Flags or indications for treatment intensification 
Several clinical or biological markers have been associated with poorer outcome. Their main 
interest is that they can point to the need for reconsidering and optimizing symptomatic 
treatment. Some of these associations may appear simple common sense but the reality is 
often more complex: in-depth statistical analysis can reveal multiple independent factors 
and it is important to bear in mind that a statistically significant association is not equivalent 
to the demonstration of a causality link. For instance, a recent Canadian study showed that 
adult patients with CF who experienced at least 3 pulmonary exacerbations per year over a 
3-year follow-up period were clearly high-risk patients, who warranted timely consideration 
for lung transplantation (de Boer et al., 2011). However, such patients were more likely to be 
female and diabetic, two risk factors linked to poorer outcome. In addition, while frequent 
pulmonary exacerbations may predispose a patient to lung transplantation, patients on the 
list for lung transplants may be more aggressively treated, thereby appearing to have more 
exacerbations. Raised serum IgG levels (Wallwork et al., 1974; Matthews et al., 1980; Wheeler 
et al., 1984; Proesmans et al., 2011) and the presence of localized auscultation anomalies 
(Konstan et al., 2007) also belong to the list of 'flags' for treatment intensification.  
6. Environmental factors  
6.1 Socioeconomic status 
As for all chronic diseases, CF prognosis is more sombre in patients of poor socio-economic 
status (SES). In 1986, there were 113 deaths registered of CF patients in the UK. Median age 
of death was 17 years overall, but it was above 20 for patients whose parents had a non-
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manual job whereas it was below 10 for the others (Britton et al., 1989). In a study of CF 
patients in the United States, the adjusted risk of death for indigent patients who qualified 
for Medicaid was 3.65 times higher than for those not receiving Medicaid. The average FEV1 
of Medicaid patients was less by 9.2% predicted than that of non-Medicaid patients, a 
difference which slightly increased by 0.54% per year of age (Schechter et al., 1998). In a CFF 
study of 23,817 white patients diagnosed before the age of 18 years, a strong association was 
found between the median household income and the mortality rate. At 6 years of age, the 
absolute differences in mean FEV1 and weight percentiles from the lowest to the highest 
income category were already very significant and they persisted into adulthood (O’Connor 
et al., 2003). Furthermore, this study also clearly showed that the relationship between 
outcome and SES was incremental, rather than dichotomous and only affecting the most 
indigent. Though access to health insurance is much better in many European countries than 
in the US, the overall costs of CF treatment and follow-up are so high that patients with low 
SES are particularly at risk of inadequate resources and poor adherence. A better 
understanding of SES-related disparities and its causes is necessary to clarify the respective 
roles of a link between poverty and other environmental factors, health behaviours and 
limited access to optimal care. Low SES has recently been associated with lower health-
related quality of life in CF patients and parents. After accounting for the effects of disease 
severity and SES, a negative effect of membership to a racial or ethnic minority on social and 
emotional functioning was also evident (Quittner et al., 2010).  
6.2 Exposure to smoking 
Exposure to passive or active smoking has deleterious effects in healthy subjects and in 
patients with respiratory diseases. An accelerated rate of FEV1 decline with age is 
documented in healthy adult smokers. Functional repercussions of passive smoking were 
assessed in a large study concerning 812 CF patients (Collaco et al., 2008). Over a fifth of 
them (188, i.e. 23%) were exposed to passive smoking. At the age of 20, the mean FEV1 of 
exposed patients was, independently of SES, 8% lower than that of non-exposed patients. 
This effect was even more pronounced in patients who were not homozygous for the 
F508del mutation, and was twice higher in patients who were also carriers of an 
unfavourable genotype with respect to the TGFß1 modifier gene. Deleterious effects of active 
smoking should a priori be more severe but have not been investigated specifically in the 
context of CF. Exposure to smoking is a major environmental factor and screening for it 
should become routine practice in CF care as several pharmacological and non-
pharmacological smoking cessation aids have proven their efficacy, the best results being 
obtained by combining modalities and tailoring therapy (Laniado-Laborin, 2010). 
6.3 Other environmental factors 
In a CF registry study, exposure to ozone and annual average exposure to particulate air 
pollution were both associated with an increased likelihood of pulmonary exacerbations. 
Exposure to particulate matter with an aerodynamic diameter of 2.5 µm or less was also 
associated with a decline in lung function (Goss et al., 2004). Though environmental factors 
are not considered the main pathogenic factors in ABPA, experts have suggested that it may 
be worth examining the patient’s environment in refractory cases (Stevens et al., 2003). 
Altough the mechanisms are unclear, recent published evidence supports a link between 
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climatic conditions (ambient temperature) and lung function in CF (Collaco et al., 2011). 
According to the authors, a hypothetical 18 year old white male with CF (Height: 175cm) 
with an FEV1 of 73.5% percent living in a cold climate would be expected to have an FEV1 
of 66.1% had he resided in a 17 degree (Celsius) warmer climate. 
Recreational use of marijuana is common in many countries. In a study of 173 adults, this drug 
was used by 20% of patients (Stern et al., 1987). In the general population, such use has been 
associated with pulmonary manifestations (bronchitis, pneumothorax, apical bullae) (Tetrault 
et al., 2007; Han et al., 2010; Gao et al., 2010) that could overlap clinical and radiological signs of 
CF, making it challenging to suspect them. Further studies seem warranted in this field. 
7. Genetic factors  
7.1 CFTR genotype 
Depending on their repercussions on the synthesis of the CF Transmembrane conductance 
Regulator (CFTR) protein, mutations of the CF gene are usually classified into 5 groups 
(Welsh et al., 1993). Mutations of classes I, II and III lead to the total or near-total absence of 
functional CFTR protein, whereas those of classes IV or V are associated to residual function 
of the CFTR protein, corresponding to a small % of normal activity. Pancreatic insufficiency 
is present in over 95% of patients carrying 2 class I, II or III mutations, whereas it is only 
rarely observed in patients carrying at least 1 class IV or V mutation (CF genotype-
phenotype consortium, 1993; Koch et al., 2001). Diabetes and severe hepatic involvement are 
2 important CF complications that usually only occur in patients with exocrine pancreatic 
insufficiency. A recent study of 505 patients registered in Israel's databases did not observe a 
single case amongst 139 pancreatic sufficient patients (Augarten et al., 2008). The 
relationship between CFTR genotype and the severity of the pulmonary involvement is 
much looser. On the whole, the genotype of patients carrying 2 mutations of class I, II or III 
is still considered high risk and is associated to earlier mortality than genotypes including at 
least 1 mutation of class IV or V ('low risk' genotypes) (Mc Kone et al., 2006). Similarly, 
although their phenotype can be extremely variable, an overall more favourable prognosis 
has been associated to some mutations of class IV or V. Amongst the latter, there are 
mutations A455E (Gan et al., 1995), 3849 +10kbC->T (Highsmith et al., 1994; Duguépéroux et 
al., 2005), 2789+5G->A (Duguépéroux et al., 2005), D1152H (Musaffi et al., 2006; Burgel et al., 
2010), R334W (Antinolo et al., 1997), 3272-26A->G (Amaral et al., 2001). The penetrance of the 
R117H mutation has convincingly been shown to be very low (Thauvin-Robinet et al., 2009) 
and is modulated by the polypyrimidine variant in the intron 8 acceptor splice site (T7 or 
T5) in cis with R117H. However, FEV1 at a given age can be extremely variable in patients 
sharing a same CFTR genotype and this is observed in patients homozygous for the F508del 
mutation as well as in patients carrying a “milder” genotype (Gan et al., 1995). In practice, 
the link between CFTR genotype and severity of lung disease is not tight, making CFTR 
genotype most often of little value in predicting the prognosis at the individual level.  
7.2 Modifier genes 
Every clinician has in mind extreme examples of the heterogeneity of functional respiratory 
progress in CF patients, including amongst those that are homozygous for the F508del 
mutation. Though poorly compliant, chronically colonized by PA since adolescence and 
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diabetic for 10 years, one 40 year-old patient keeps his FEV1 above 80% of the predicted 
value whereas a young lady, with an optimal follow-up since birth and only occasionally 
Aspergillus fumigatus in sputum experiences a rapid functional decline from age 12 and 
requires a lung transplantation at 20. Environmental factors may play a role but admittedly 
such patients have to be either 'protected' for one or 'condemned' for the other, by particular 
allele combinations of modifier genes probably modulating the immune and inflammatory 
response in the lungs. 
Family-based studies and especially comparisons of monozygous and dizygous twin pairs 
have proven fruitful in identifying and assessing the contribution of modifier genes in CF 
disease. Many studies in this field have yielded conflicting results and it is now realized that 
the repeatability of SNP–phenotype association studies with positive findings was low 
when less than 500 participants were included (Boyle, 2007). More recent studies are more 
powerful and use more sophisticated tools including whole-genome methods. Quite 
convincing evidence is now available that variants of at least 3 genes can be associated with 
lung disease severity in CF (Cutting, 2010): i) MBL2-deficient (10q) genotype: in normal 
subjects, mannose binding lectin (MBL) aids the phagocytosis of bacteria and deficiency in 
MBL seems to predispose to early infection with PA in CF ii) Increased TGFß1 (19q) 
expression (Drumm et al., 2005): this gene, which also modulates the risk for asthma and 
chronic obstructive pulmonary disease, encodes a cytokine playing a role in the regulation 
of inflammation and tissue remodelling iii) Increased EDNRA (4q) expression: Endothelin is 
a proinflammatory peptide and smooth muscle agonist which is increased in CF airways. 
Deleterious effects could be related to an impact on smooth muscle tone in the airways 
and/or vasculature (Darrah et al., 2010). More recently, two loci causing variations in CF 
lung disease severity have been identified on chromosomes 11p and 20q respectively 
(Wright et al., 2011). Variation in TCF7L2 (10q) was reported to increase the risk of diabetes 
about threefold and even more in patients without previous treatment with systemic 
steroids (Blackman et al., 2009). Variants of other genes are suspected to increase the risk of 
liver cirrhosis (Bartlett et al., 2009) or meconium ileus. Further progress in the identification 
of modifier genes should result in an increased ability to predict severity of CF disease, and 
hopefully be accompanied by new perspectives for therapeutic intervention. 
8. Conclusions  
For patients, their relatives and also their carers, facing CF is often compared to running a 
long-distance race. It is also a team race, where no-one can let go. In terms of life expectancy, 
prognosis of the disease has been improving continuously since 40 years. However, it is almost 
always impossible to predict CF prognosis at the individual level. The quality of an early 
global care management is an essential prognostic determinant. Further progress in 
symptomatic CF treatment remains necessary, especially towards better prevention of 
respiratory involvement in early-diagnosed newborns and in the field of immunosuppression 
in lung transplantation. The discovery of a cure for the respiratory disease in CF would be a 
real breakthrough. A pharmacological approach tailored to the class mutations of the CFTR 
gene appears currently the most encouraging route in this direction. 
Meanwhile, the essence of the carer’s role today remains founded on these two maxims: 'Do 
not abandon the marathon' and 'Always try to do better'. 
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